Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote (1)	1/4/2000 4:07:00 AM
From: michael_f_murphy	Read Replies (1) of 625

The stock has been down then flat since 1997 IPO now popping up on news of collaboration with big pharma. Seem to have stock of cash (FY 98). Hard to find detail on interim results. Need some help on how to further research finances and science. Some info gleaned from the web site: cambridgeantibody.com Closing Share price on 30-Dec-1999 : 638p No of shares in issue : 25.262m Market Capitalisation on 30-Dec-1999: œ161m Pipeline (May 1999) D2E7 Rheumatoid arthritis TNF-alpha In Phase II trials conducted by BASF. New data will be presented by BASF Pharma at the EULAR 99 Conference in Glasgow, June 1999. CAT-152 Glaucoma Surgery TGF-beta2 Patient recruitment for first Phase I/IIa clinical study complete. Phase II clinical trials to start in summer. CAT-192 Fibrosis - Local and Systemic TGF-beta1 Phase I start due late 1999 - local Phase I/IIa start expected 2000 - systemic J695 Autoimmunity/Inflammation IL-12 BASF/GI to commence Phase I clinical study this summer Dr David Chiswell BSc PhD Chief Executive Officer David Chiswell was a founder of CAT. He has been responsible for operational management since foundation and was appointed a director in December 1995. Previously, he spent nine years at Amersham International plc where he held a number of posts combining responsibilities for product development and research management. Prior to moving into the commercial sector in 1981 he gained research experience in the field of molecular retrovirology at the MRC Institute of Virology in Glasgow, the department of Immunology and Microbiology at UCLA in California and the department of Tumour Virology at the Imperial Cancer Research Fund in London.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next